JR4-187

JR4-187 is an orally active copper-dependent anti-cancer agent. It downregulates genes involved in oxidative phosphorylation, MYC targets, and E2F targets, while upregulating genes associated with the TNF-α signaling pathway, p53 pathway, and KRAS signaling pathway, in addition to reducing CTR1 protein levels. JR4-187 induces ROS production, apoptosis (apoptosis), and copper-dependent cytotoxicity, with selective cytotoxicity towards KRAS mutant cancer cells. It exhibits good tolerability in pancreatic cancer mouse models. JR4-187 is applicable for research in pancreatic ductal adenocarcinoma, colon cancer, rectal cancer, and other related cancers.